{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Malignant+Tumors&page=2", "query": { "condition": "Advanced Solid Malignant Tumors", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Malignant+Tumors&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T05:25:21.742Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01898078", "title": "Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2013-07-16", "completion_date": "2017-01-24", "has_results": true, "last_update_posted_date": "2019-06-21", "last_synced_at": "2026-09-29T05:25:21.742Z", "location_count": 3, "location_summary": "The Bronx, New York • Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01898078" }, { "nct_id": "NCT05322408", "title": "HCW9218 in Select Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "HCW9218", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-04-01", "completion_date": "2025-02-28", "has_results": true, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-09-29T05:25:21.742Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05322408" }, { "nct_id": "NCT02031055", "title": "Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "TAS-102 with a light tracer dose of [14C]FTD", "type": "DRUG" }, { "name": "TAS-102 with a light tracer dose of [14C] TPI", "type": "DRUG" }, { "name": "TAS-102 tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2014-02", "completion_date": "2015-06-17", "has_results": false, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-09-29T05:25:21.742Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02031055" }, { "nct_id": "NCT00352443", "title": "S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "lapatinib ditosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2006-09", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-09-29T05:25:21.742Z", "location_count": 6, "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00352443" }, { "nct_id": "NCT04729725", "title": "SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Anti-TGF-beta Monoclonal Antibody SAR-439459", "type": "BIOLOGICAL" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2021-02-09", "completion_date": "2022-12-02", "has_results": false, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-09-29T05:25:21.742Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729725" }, { "nct_id": "NCT06287463", "title": "Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "RAF Mutation", "RAS Mutation", "NF1 Mutation", "Non-Small Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Melanoma", "BRAF Gene Mutation", "CRAF Gene Mutation", "Castration-Resistant Prostate Cancer (CRPC)" ], "interventions": [ { "name": "DCC-3084", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deciphera Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2024-05-14", "completion_date": "2026-02-13", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-29T05:25:21.742Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06287463" }, { "nct_id": "NCT03156114", "title": "This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Ezabenlimab", "type": "DRUG" }, { "name": "BI 754111", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2017-06-13", "completion_date": "2023-06-06", "has_results": true, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-09-29T05:25:21.742Z", "location_count": 6, "location_summary": "Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03156114" }, { "nct_id": "NCT07636785", "title": "A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma (HCC)", "Metastatic Uveal Melanoma", "Renal Cell Carcinoma (RCC)", "Nonsmall Cell Lung Cancer", "Colorectal Cancer (CRC)" ], "interventions": [ { "name": "VMD-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VM Discovery, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 111, "start_date": "2026-07-16", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-29T05:25:21.742Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07636785" }, { "nct_id": "NCT00638898", "title": "Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Adult Central Nervous System Germ Cell Tumor", "Adult Rhabdomyosarcoma", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Soft Tissue Sarcoma", "Ewing Sarcoma", "Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Ovarian Mixed Germ Cell Tumor", "Previously Untreated Childhood Rhabdomyosarcoma", "Recurrent Adult Brain Tumor", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Extragonadal Germ Cell Tumor", "Recurrent Extragonadal Non-seminomatous Germ Cell Tumor", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Neuroblastoma", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "40 Years", "sex": "ALL", "summary": "6 Months to 40 Years" }, "enrollment_count": 25, "start_date": "2007-02-26", "completion_date": "2024-12-10", "has_results": false, "last_update_posted_date": "2025-03-20", "last_synced_at": "2026-09-29T05:25:21.742Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00638898" }, { "nct_id": "NCT01661972", "title": "Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Capecitabine and aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Strickler, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2012-08", "completion_date": "2016-06-12", "has_results": true, "last_update_posted_date": "2018-10-29", "last_synced_at": "2026-09-29T05:25:21.742Z", "location_count": 2, "location_summary": "Durham, North Carolina • Norfolk, Virginia", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01661972" } ] }